• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PanTher Therapeutics

PanTher Therapeutics

  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact
homePress ReleasePanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer

October 6, 2021 Press Release

PanTher announced today the dosing of the first two patients in its Phase 1 clinical trial of PTM-101 for the treatment of pancreatic cancer. This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma. “Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors,” said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. “We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer.”

Footer

Twitter LinkedIn

PanTher Therapeutics, Inc

191 Dexter Ave
Watertown, MA, 02472

PanTher Therapeutics © 2022 All Rights Reserved

Terms of Use Privacy Policy Cookie Policy Accessibility Statement

logo
  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact